Literature DB >> 20809185

Potential role of serum level of soluble CD44 and IFN-γ in B-cell chronic lymphocytic leukemia.

Nervana Samy1, M D Abd El-Maksoud, T E Mousa, Hatem A El-Mezayen, Mohamed Shaalan.   

Abstract

Evidence indicates that the slowly expanding population of B cells that characterizes chronic lymphocytic leukemia (CLL) results primarily from defects in responses to cytokines. We evaluated the prognostic value of soluble CD44 and IFN-γ in B-cell chronic lymphocytic leukemia (B-CLL) and analyzed their source and regulation secretion in B-CLL clones in vitro. Levels of soluble CD44 standard (sCD44s) and IFN-γ were analyzed by enzyme-linked immunosorbent assay. B-CLL cells were separated and stimulated in vitro for the detection of both markers. Serum levels of sCD44s and IFN-γ were significantly elevated in patients with B-CLL in comparison with normal persons. Elevated levels of sCD44s and IFN-γ were associated with an advanced disease as reflected by increased values as stage progress. In B-CLL, sCD44s as well as IFN-γ was shed from leukemia cells as shown by in vitro cultures. Stimulation of B-CLL clones results in a proliferation-associated increased secretion of sCD44s and IFN-γ. B-CLL clones from advanced-stage patients are characterized by an increased capacity for proliferation and production of both markers in comparison with early-stage patients. Our present results suggest that sCD44 and IFN-γ may be of major importance in the pathogenesis of B-CLL, and inhibition of the effects of sCD44 and IFN-γ could be a potential therapeutic strategy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20809185     DOI: 10.1007/s12032-010-9661-6

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  22 in total

1.  The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells.

Authors:  Mohammad Luqman; Sha Klabunde; Karen Lin; Georgios V Georgakis; Anu Cherukuri; Jocelyn Holash; Cheryl Goldbeck; Xiaomei Xu; Edward E Kadel; Sang Hoon Lee; Sharon Lea Aukerman; Bahija Jallal; Natasha Aziz; Wen-Kai Weng; William Wierda; Susan O'Brien; Anas Younes
Journal:  Blood       Date:  2008-05-22       Impact factor: 22.113

Review 2.  The interferon receptors.

Authors:  S Pestka
Journal:  Semin Oncol       Date:  1997-06       Impact factor: 4.929

3.  Chronic lymphocytic leukemia: recommendations for diagnosis, staging, and response criteria. International Workshop on Chronic Lymphocytic Leukemia.

Authors: 
Journal:  Ann Intern Med       Date:  1989-02-01       Impact factor: 25.391

4.  Elevated serum levels of soluble CD44 can identify a subgroup of patients with early B-cell chronic lymphocytic leukemia who are at high risk of disease progression.

Authors:  S Molica; G Vitelli; D Levato; D Giannarelli; G M Gandolfo
Journal:  Cancer       Date:  2001-08-15       Impact factor: 6.860

5.  Growth factors can protect B-chronic lymphocytic leukaemia cells against programmed cell death without stimulating proliferation.

Authors:  A P Jewell; P M Lydyard; C P Worman; F J Giles; A H Goldstone
Journal:  Leuk Lymphoma       Date:  1995-06

6.  Elevated serum levels of soluble CD44 variant 6 are correlated with shorter survival in aggressive non-Hodgkin's lymphoma.

Authors:  K Sasaki; N Niitsu
Journal:  Eur J Haematol       Date:  2000-09       Impact factor: 2.997

7.  Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study.

Authors:  Asher Chanan-Khan; Kena C Miller; Laurie Musial; David Lawrence; Swaminathan Padmanabhan; Kenichi Takeshita; Carl W Porter; David W Goodrich; Zale P Bernstein; Paul Wallace; David Spaner; Alice Mohr; Catriona Byrne; Francisco Hernandez-Ilizaliturri; Cynthia Chrystal; Petr Starostik; Myron S Czuczman
Journal:  J Clin Oncol       Date:  2006-11-06       Impact factor: 44.544

8.  Expression and shedding of CD44 variant isoforms in patients with gynecologic malignancies.

Authors:  D D Taylor; C Gercel-Taylor; S A Gall
Journal:  J Soc Gynecol Investig       Date:  1996 Sep-Oct

Review 9.  A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group.

Authors:  N L Harris; E S Jaffe; H Stein; P M Banks; J K Chan; M L Cleary; G Delsol; C De Wolf-Peeters; B Falini; K C Gatter
Journal:  Blood       Date:  1994-09-01       Impact factor: 22.113

Review 10.  Prognostic features and therapeutical approaches in B-cell chronic lymphocytic leukemia: an update.

Authors:  S Molica; G De Rossi; M Luciani; D Levato
Journal:  Haematologica       Date:  1995 Mar-Apr       Impact factor: 9.941

View more
  4 in total

1.  Combined CXCR3/CXCR4 measurements are of high prognostic value in chronic lymphocytic leukemia due to negative co-operativity of the receptors.

Authors:  Sylvia Ganghammer; Julia Gutjahr; Evelyn Hutterer; Peter W Krenn; Susanne Pucher; Claudia Zelle-Rieser; Karin Jöhrer; Maikel Wijtmans; Rob Leurs; Martine J Smit; Valter Gattei; Richard Greil; Tanja N Hartmann
Journal:  Haematologica       Date:  2015-11-20       Impact factor: 9.941

2.  The PD-1/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia.

Authors:  Davide Brusa; Sara Serra; Marta Coscia; Davide Rossi; Giovanni D'Arena; Luca Laurenti; Ozren Jaksic; Giorgio Fedele; Giorgio Inghirami; Gianluca Gaidano; Fabio Malavasi; Silvia Deaglio
Journal:  Haematologica       Date:  2013-01-08       Impact factor: 9.941

3.  The Breast Cancer to Bone (B2B) Metastases Research Program: a multi-disciplinary investigation of bone metastases from breast cancer.

Authors:  Nigel T Brockton; Stephanie J Gill; Stephanie L Laborge; Alexander H G Paterson; Linda S Cook; Hans J Vogel; Carrie S Shemanko; David A Hanley; Anthony M Magliocco; Christine M Friedenreich
Journal:  BMC Cancer       Date:  2015-07-10       Impact factor: 4.430

4.  C-C motif ligand 11 reduction in CLL patients serum after vitamin D supplementation.

Authors:  Marcin Kubeczko; Elżbieta Nowara; Dobromiła Karwasiecka; Grażyna Siewior; Paulina Czajka-Francuz; Jerzy Chudek; Jerzy Wojnar
Journal:  Hematology       Date:  2016-03-01       Impact factor: 2.269

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.